Streetbeat News

Revenues

MDXH

MDxHealth has reaffirmed its revenue guidance for 2024, projecting revenues between $79M and $81M, aligning with the estimated $79.629M. The company also confirmed its expectation to achieve adjusted EBITDA profitability in the first half of 2025.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 9:40 pm

CMPO

CompoSecure projects its FY24 net sales to be between $408M and $428M, which is around the current estimate of $417.71M.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 9:40 pm

VSEC

VSE Corp is exploring strategic alternatives for its Fleet segment, including a potential corporate restructuring plan and relocating its headquarters.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 9:36 pm

KEQU

Kewaunee Scientific (NASDAQ:KEQU) reported a significant increase in Q3 EPS to $0.85, up from $0.25 YoY, despite a 23.09% decrease in sales to $46.78M from $60.82M YoY.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 9:30 pm

CORZ

Core Scientific has entered into a long-term hosting contract with CoreWeave, providing up to 16 MW of data center infrastructure to support AI and HPC workloads, potentially generating over $100M in revenue. This strategic move leverages Core Scientific's expertise in high-value compute, expanding its revenue model to include customers in the rapidly growing HPC sector. The company has leased a data center in Austin, TX, previously occupied by Hewlett Packard, to facilitate this growth. The contract is expected to be accretive to Core Scientific's earnings in 2024.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 9:30 pm

COHN

Cohen & Company reported a significant increase in its Q4 2024 adjusted EPS to $2.88, up from a loss of $(1.13) in the same quarter the previous year. Revenue also saw a substantial rise to $34.464 million from $12.450 million year-over-year.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 9:27 pm

RSI

Rush Street Interactive projects its 2024 revenue to be between $770M and $830M, surpassing the estimated $759.25M. This forecast indicates a positive outlook for the company's financial growth.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 9:24 pm

CDXC

ChromaDex projects its revenue growth in 2024 to surpass the previous year's growth rate of 16%, indicating a positive trajectory for the company's financial performance.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 9:23 pm

EBS

Emergent BioSolutions projects its FY24 revenue to be between $900 million and $1.10 billion, which is below the estimated $1.184 billion.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 9:22 pm

EBS

Emergent BioSolutions projects its Q1 2024 revenue to be between $200M-$250M, surpassing the estimated $185.4M.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 9:21 pm